Abstract: Embodiments herein describe techniques for a memory device including at least two memory cells. A first memory cell includes a first storage cell and a first transistor to control access to the first storage cell. A second memory cell includes a second storage cell and a second transistor to control access to the second storage cell. A shared contact electrode is shared between the first transistor and the second transistor, the shared contact electrode being coupled to a source area or a drain area of the first transistor, coupled to a source area or a drain area of the second transistor, and further being coupled to a bit line of the memory device. Other embodiments may be described and/or claimed.

Abstract: An environmental control device (100, 200), such as a thermostat, is disclosed. The environmental control device (100, 200) has one or more terminals (104, 104a-104i) for connecting to an HVAC system (14) and performs over current management of the terminal (104, 104a-104i) when connected to the HVAC system (14).

Abstract: An environmental control device (100), such as a thermostat, is disclosed. The environmental control device (100) has one or more terminals (222, 222a-222d) and a respective configurable interface circuit (102, 102a-102d, 300) coupled to each terminal for selectively configuring the terminal (222, 222a-222d) for a corresponding input or output connection to an HVAC system (14).

Abstract: An environmental control device (100, 200), such as a thermostat, is disclosed. The environmental control device (100, 200) has one or more terminals (104, 104a-104i) for connecting to an HVAC system (14) and performs over current management of the terminal (104, 104a-104i) when connected to the HVAC system (14).

Abstract: An environmental control device (100), such as a thermostat, is disclosed. The environmental control device (100) has one or more terminals (222, 222a-222d) and a respective configurable interface circuit (102, 102a-102d, 300) coupled to each terminal for selectively configuring the terminal (222, 222a-222d) for a corresponding input or output connection to an HVAC system (14).

Abstract: Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.

Abstract: Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.

Abstract: In general, in one aspect, a display controller has non-essential portions powered off for a portion of vertical blanking interval (VBI) periods to conserve power. The portion takes into account overhead for housekeeping functions and memory latency for receiving a first packet of pixels for a frame to be decoded during a next active period. Gating circuitry may gate power to the non-essential portions starting at beginning of the VBI periods. A latency predictor may predict the portion of the VBI periods by predicting the memory latency for a next VBI period and subtracting the predicted memory latency from the VBI period. The memory latency for the next VBI period may be predicted by adding an average difference between successive actual memory latencies for a plurality of VBI periods to an actual memory latency for previous VBI period. A constant delay may also be subtracted from the VBI period.

Abstract: Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.

Abstract: Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.

Abstract: Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.

Abstract: Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.

Abstract: Various embodiments of the invention provide human kinases and phosphatases (KPP) and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.

Abstract: The invention provides for compositions comprising engineered Her3 multimers with improved binding affinity. Such multimers include, but are not limited to, Her1/Her 3 heterodimers in which the Her3 ligand binding domain has been optimized to increase binding to Her3. The composition also can include mixtures of Her 1 homodimers, Her 3 homodimers, and Her 1/Her 3 heterodimers.

Abstract: Provided are pan-cell surface receptor-specific therapeutics, methods for preparing them and methods of treatment using them. Among the pan-cell surface receptor-specific therapeutics are pan-HER-specific therapeutics that interact with at least two different HER receptor ligands and/or dimerize with or interact with two or more HER cell surface receptors. By virtue of these properties, the therapeutics modulate the activity of at least two cell surface receptors and are useful for therapeutic purposes.

Abstract: Isoforms of cell surface receptors, including isoforms of receptor tyrosine kinases, and pharmaceutical compositions containing the isoforms are provided. Chimeras of and conjugates containing the cell surface receptors that contain a portion, such as an extracellular domain, from one cell surface receptor, and a second portion, particularly an intron-encoded portion, from a second cell surface protein also are provided. The isoforms modulate the activity of a cell surface receptor. Methods for identifying and preparing isoforms of cell surface receptors including receptor tyrosine kinases are provided. Also provided are methods of treatment with the cell surface receptor isoforms.

Abstract: Various embodiments of the invention provide human receptors and membrane-associated proteins (REMAP) and Q polynucleotides which identify and encode REMAP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of REMAP.

Abstract: Various embodiments of the invention provide human cell adhesion and extracellular matrix proteins (CADECM) and polynucleotides which identify and encode CADECM. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of CADECM.

Abstract: Various embodiments of the invention provide human extracellular messengers (EXMES) and polynucleotides which identify and encode EXMES. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of EXMES.

Abstract: Provided are methods for production of cell surface receptor (CSR) and ligand isoforms. In particular, isoform fusions that a precursor sequence for secretion, processing and intracellular trafficking are provided. Nucleic acid molecules encoding the fusions are expressed in a host cell and the encoded and partially or completely processed encoded CSR or ligand isoforms is produced in the cell culture medium. The resulting polypeptide optionally includes an epitope tag for the detection and/or purification thereof.